Key result
Olmesartan medoxomil, either alone or in combination with calcium channel blockers and diuretics, effectively reduces and stabilizes blood pressure in patients with hypertension.
Why the study?
Does olmesartan medoxomil alone or in combination improve blood pressure control and reduce adverse events in patients with hypertension?
Does olmesartan medoxomil alone or in combination improve blood pressure control and reduce adverse events in patients with hypertension?
Olmesartan medoxomil, alone or in combination with CCBs and diuretics, is an effective and safe treatment for hypertension.
May support olmesartan for hypertension control; leaves open need for RCTs on outcomes versus other ARBs.
Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2017) conducted a review in Hypertension. Olmesartan medoxomil was evaluated. Olmesartan medoxomil, either alone or in combination with calcium channel blockers and diuretics, effectively reduces and stabilizes blood pressure in patients with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: